BioSpace News Archive

Helix BioPharma Corp. announces that it has closed a private placement financing for net proceeds of $2,002,000 from the issuance of 7,700,000 common shares at a price of $0.26 per common share.

Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces a Non-Clinical Evaluation Agreement (NCEA) with the National Institute of Allergy and Infectious Diseases (NIAID) for exploratory preclinical studies to evaluate the potential of Cocrystal’s 3CL protease inhibitors for the treatment of COVID-19.

Impel NeuroPharma announced that Chairman of the Board and Chief Executive Officer, Adrian Adams will ring the Nasdaq Stock Market closing bell on Monday, April 25, 2022.

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the appointment of E. Rene Salas to the Intra-Cellular Therapies Board of Directors.

Aileron Therapeutics announced it has expanded its management team with the appointment of Christopher Zergebel as Vice President of Program Management and Clinical Operations.

Codexis, Inc. and seqWell, Inc. announced the initiation of a strategic partnership and investment to accelerate the commercialization of seqWell’s genomics workflow solutions.

Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, May 5, 2022 at 4:30 p.m. Eastern time to discuss the financial results for the first quarter of 2022.

AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), today provided a summary of clinical data that support the synergistic potential of Ampligen® (rintatolimod) with checkpoint blockade therapies.

Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), announced today that the final patient has been enrolled in the European Union (EU) study of the Pure-Vu System, which is evaluating the clinical outcomes in patients with a history of poor bowel preparation using both a low volume preparation with limited diet restrictions and the Pure-Vu System.

Sotera Health Company, a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced its plans to release its financial results for the first quarter ended March 31, 2022 before market open on Thursday, May 5, 2022.